SeaStar Medical Holding Corporation ICU 深 滬
已收盤 04-24 16:00:00 美东时间
4.13
-0.110
-2.59%
華盛通- 最 高4.3953
- 今 開4.33
- 成交量 13.39万股
- 最 低 4.05
- 昨 收 4.24
- 總市值 1649.41万
- 52周最高 13.399
- 市盈率 靜 --
- 換手率 3.35%
- 52周最低 2.07
- 委 比 72.86%
- 總股本 399.37万
- 歷史最高 3050.00
- 量 比 1.19
- 振 幅 8.14%
- 歷史最低 2.20
- 每 手 1
- 風險率 3.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
SeaStar Medical announced new data from the SAVE Registry, showing no device-related adverse events and strong survival rates in pediatric patients with AKI and sepsis treated with its SCD therapy. In vitro research highlights the device's immunomodulatory effects, shifting monocytes to an anti-inflammatory state. The company also hosted a symposium on pediatric AKI innovation, underscoring its leadership in this field.
03-30 12:20
SeaStar Medical Holding Q4 EPS $(0.80) Beats $(1.01) Estimate, Sales $420.000K Beat $372.500K Estimate
SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.01) by 21.18 percent. This is a 91.11 percent increase over losses of $(9.00) per share
03-26 04:07
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
SeaStar Medical Holding Corporation will report its Q4 and year-end 2025 financial results on March 25, 2026, and host a webcast and conference call at 4:30 p.m. ET to discuss its financial performance and business progress. The webcast and call registration details are available online. The company, focused on treating critically ill patients with organ failure, markets QUELIMMUNE (SCD-PED) for life-threatening AKI in pediatric patients and is c...
03-18 20:05
SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI
SeaStar Medical announced the completion of patient enrollment in the FDA-required SAVE Registry, a post-approval study to confirm the safety of QUELIMMUNE therapy for children with AKI due to sepsis. With 50 patients enrolled, the company will report 28-day safety data to the FDA later this year. QUELIMMUNE, approved in 2024, has shown promising results in clinical trials, including a 77% survival rate in treated patients, and is being used in l...
03-05 13:20
SeaStar Medical Publishes Data On Early Post-Approval Clinical Experience From Use Of QUELIMMUNE Device For Pediatrics Therapy
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective
02-09 21:24
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
SeaStar Medical announced QUELIMMUNE therapy's positive early data in treating critically ill pediatric AKI and sepsis patients, published in *Pediatric Nephrology*. The SAVE Registry findings show a 71% survival rate at 90 days, no device-related adverse events, aligning with clinical trial results. The therapy may reduce patient mortality by 50%, offering significant benefits with minimal safety risks.
02-09 13:20
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
SeaStar Medical Holding Corporation announced that CEO Eric Schlorff will present at Noble Capital Markets’ conference on February 5th. Interested parties can register for the live presentation or access the replay on February 9th. SeaStar Medical specializes in transforming treatments for critically ill patients, with its QUELIMMUNE therapy approved for life-threatening acute kidney injury in pediatric patients. The company is also conducting p...
01-29 13:25
SeaStar Medical Announces 2026 Milestones
SeaStar Medical outlines 2026 milestones to expand QUELIMMUNE adoption for ultra-rare pediatric AKI, advance the NEUTRALIZE-AKI pivotal trial for adult AKI, and explore broader applicability of its SCD therapy in heart failure patients. The company aims to double its customer base, achieve $2 million in revenue, and leverage FDA designations to accelerate approvals. Recent achievements include successful interim trial results, real-world data val...
01-07 13:13
SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference
SeaStar Medical's CEO, Eric Schlorff, will present at the Biotech Showcase 2026 on January 13, 2026, at 3:00 p.m. PST. The live presentation and replay will be available on the company’s website. Additionally, SeaStar’s management will meet with investors during the J.P. Morgan Healthcare Conference in San Francisco on January 12-14, 2026. The company’s QUELIMMUNE (SCD-PED) therapy for life-threatening acute kidney injury in pediatric patients wa...
01-06 13:53
